Teva in Q1: innovative medicines are carrying growth, but cash quality still needs proof

Company Overview

Teva entered 2026 with a business story that has clearly changed, but not yet fully resolved. The company still has a broad generics base, a U.S. distribution business, an API operation classified as held for sale and a biosimilar pipeline. Yet the first quarter shows that the real economic driver is now a narrower set of innovative medicines: AUSTEDO, AJOVY and UZEDY. They are growing quickly, lifting gross margin and carrying the company’s strategic move toward biopharma.

Still, this is not a quarter that can be read only through revenue and earnings. Reported revenue rose to $3.982 billion, up 2% in U.S. dollars, but declined 3% in local-currency terms. In other words, a meaningful part of the reported improvement came from foreign exchange, not only from better volume, pricing or product mix. Operating income rose to $652 million, but operating cash flow was negative $40 million. Reported free cash flow of $188 million was built mainly from $354 million collected from beneficial interests in securitized European receivables and another $42 million from asset sales.

The active bottleneck for Teva is cash quality, not growth itself. The innovative medicines are working. The pipeline is moving. The company is even willing to acquire Emalex for $700 million in cash and to consider a share repurchase program. But the same cash balance also has to fund $16.627 billion of debt, $4.680 billion of legal settlement and loss contingency provisions, capital investments, legal payments and a development pipeline that is becoming more expensive. That makes 2026 a proof year: can the product improvement become recurring operating cash flow, or is it mostly offsetting generics erosion, litigation and active working-capital management?

The easy point to miss is that the strategic shift is no longer theoretical. The key innovative medicines generated about $837 million in the quarter, compared with about $589 million in the prior-year quarter, an increase of roughly $248 million. At the same time, generic product revenues across the three reported segments declined from about $2.306 billion to about $2.087 billion. This is a quarter in which innovation is more than offsetting part of the erosion, but it still has not released the company from the cash test.

A Compact Economic Map

Events and Triggers

The first trigger: Emalex turns the capital allocation debate into a real cash event. Teva signed an April agreement to acquire Emalex, including ecopipam, a pediatric Tourette syndrome treatment that has completed Phase 3. The upfront payment at closing is $700 million in cash, with up to $200 million in additional milestones and royalties after commercialization and subject to regulatory approval. Closing is expected in the third quarter of 2026. The transaction strengthens the neurology franchise, but it also uses cash before approval and before revenue. It improves the growth profile, while reducing the margin for error in cash deployment.

The second trigger: pipeline funding partnerships lower current expense but share future value. Blackstone agreed to provide up to $400 million over four years to fund duvakitug development. In exchange, it may receive a milestone payment approximately equal to the funding amount, plus commercial milestones and royalties upon commercialization. In the first quarter, Teva recognized $30 million of R&D expense reimbursement under this agreement. Abingworth provided another $30 million of reimbursement around DARI, and Royalty Pharma opened a potential funding framework of up to $500 million for TEV-408, including $75 million after Phase 1b results and an option for another $425 million. This is a sensible way to manage development risk, but it is not free value. If the products succeed, part of the economics goes to partners.

The third trigger: olanzapine LAI has reached the regulatory stage. The NDA was submitted in December 2025 and accepted by the FDA in February 2026. Together with UZEDY, which received an October 2025 expanded indication for maintenance treatment of bipolar 1 disorder in adults, Teva is building a broader CNS layer. That reduces future dependence on AUSTEDO alone, but it does not change 2026 results without approval, launch and sales conversion.

The fourth trigger: API remains an asset waiting for resolution. At the end of March, API assets held for sale stood at $1.794 billion, against $334 million of liabilities and an expected $283 million loss on sale already embedded in the classification. API third-party sales fell 17% to $109 million in the quarter. The sale process fits the focus strategy, but until a transaction is completed, the company still carries a shrinking activity that consumes management attention.

The fifth trigger: the share repurchase is still a planning signal, not an approved program. The board instructed management to plan for a potential repurchase program, subject to distribution and solvency tests, market conditions, the share price and alternative growth investments. A prior analysis of Emalex and the potential repurchase already framed that tension. In this article, the broader implication is capital discipline: if Teva uses cash for repurchases before operating cash flow becomes stronger, the market may read the move as premature.

Efficiency, Profitability and Competition

Profitability improved, but not because every part of the company improved equally. Gross profit rose to $1.972 billion and gross margin improved to 49.5%, from 48.2% in the prior-year quarter. The economic explanation is straightforward: AUSTEDO grew quickly in the U.S., and innovative medicines are shifting the sales base toward higher-margin products. At the same time, lenalidomide erosion in the U.S. and broader generics pressure still pull in the opposite direction.

The U.S. segment shows both movements at once. Revenue was almost unchanged at $1.534 billion, but generics fell 28% to $612 million, mainly because of lenalidomide. AUSTEDO rose 41% to $559 million, AJOVY rose 64% to $87 million and UZEDY rose 62% to $63 million. This mix improved U.S. gross margin to 67.7%, but U.S. selling and marketing expenses rose 22% to $298 million, mainly around key innovative products. Segment profit therefore declined 2%, even though the sales base became higher quality.

That matters. Innovative-medicine growth is not costless. Teva is buying awareness, physician access, coverage and continuity through commercial investment. That is legitimate while building a new engine, but it means the next read should test not only product sales, but also how much spending is required to sustain them.

Europe looks strong in dollars and weaker in local currency. Revenue rose 12% to $1.340 billion, but declined 1% in local-currency terms. AJOVY grew 31% in dollars and 17% in local currency, but generics and OTC declined in local currency, while COPAXONE kept eroding. Segment profit still increased 22% to $401 million, so Europe remains highly profitable. The quarter, however, does not prove underlying European growth. It proves more about FX support and profitability control.

International Markets remain the weak point. Revenue declined 10% to $524 million, or 19% in local-currency terms, and segment profit fell 33% to $65 million. The Japan business venture divestiture explains a meaningful part of the decline, but generic products also fell to $386 million. AUSTEDO and AJOVY are growing outside the U.S., but they are still too small to change the whole segment.

The bottom line also needs cleaning. Net income attributable to Teva rose to $369 million from $214 million, and diluted EPS rose to $0.31. On a non-GAAP basis, net income was $621 million and diluted EPS was $0.53, only slightly ahead of $0.52 a year earlier. The gap between GAAP and non-GAAP is still wide, driven by amortization, litigation, restructuring, share-based compensation and other items. The conclusion is not that the improvement is artificial. It is that reported earnings still pass through many filters before reaching recurring earnings power.

Cash Flow, Debt and Capital Structure

The all-in cash picture for the first quarter is simpler than the headline and less flattering. This is not a normalized cash generation framework. It is the period’s full cash bridge after operating cash flow, receivables securitization, asset sales and capital investments. On that basis, Teva reported $188 million of free cash flow. But within that number, operating cash flow was negative $40 million, capital investments were $168 million, and the positive cash contribution mainly came from $354 million collected from beneficial interests in securitized receivables and $42 million from asset sales.

Management attributes the improvement versus the prior-year quarter to favorable timing of sales and collections in the U.S. and lower interest payments, partly offset by higher employee performance incentive payments. That is an improvement, but it does not replace the core test: negative operating cash flow in a quarter with $369 million of net income means the gap between profit and cash is still large. Part of it may be timing and seasonality. For a company discussing acquisitions and repurchases, it is still a number investors cannot ignore.

Securitization is not a problem by itself. It is a legitimate receivables financing tool. But when reported free cash flow depends on it, that cash line should be read differently. In the U.S. securitization program, pledged receivables declined to $462 million at the end of March from $799 million at year-end 2025. Supplier finance program obligations increased to $251 million from $225 million. These figures do not erase the improvement, but they show that working capital is still being managed actively.

Debt declined only slightly in the quarter, from $16.807 billion to $16.627 billion, mainly because of $174 million of FX impact. Cash rose to $3.741 billion, bringing simple net debt to about $12.886 billion. That improves financial flexibility, but it is not a structural reset. Short-term debt rose to 16% of total debt from 11% at year-end 2025, and current maturities of long-term liabilities stood at $2.600 billion.

The $1.8 billion revolving credit facility remains undrawn, and its maturity was extended to April 2028. The key covenant limits leverage to 4.25x, and Teva expects not to exceed the covenant thresholds within the next year based on current and forecasted results. That is an important positive signal. It lowers immediate liquidity risk, but it does not answer whether core cash flow can reduce debt while funding acquisitions, legal payments and pipeline investment.

The legal tail remains one of the main cash uses. The provision for legal settlements and loss contingencies declined to $4.680 billion from $4.753 billion at year-end 2025, a decrease of only $73 million. Legal settlement and loss contingency expenses were $72 million in the quarter, mainly due to the time value update on opioid settlement payments. In opioids, Teva expects cash payments of $379 million in 2026, of which $30 million had been paid by March 31, $365 million in 2027, $416 million in 2028, $339 million in 2029 and $337 million in 2030. The DOJ PAP settlement adds $49 million due in December 2026, $49 million in December 2027, $99 million in December 2028 and $175 million in December 2029, after $34 million paid in January 2026.

Outlook

Three non-obvious findings shape the 2026 read. First, dollar growth masks local-currency decline. Second, profitability is improving mainly because of the U.S. innovative-medicine mix, but sustaining that mix requires higher commercial spending. Third, positive free cash flow still came through securitization and asset sales, while operating cash flow itself used cash.

That makes 2026 a proof year, not a clean breakout year. If AUSTEDO, AJOVY and UZEDY keep growing at high double-digit rates, the company can show quality improvement even as generics erode. If their growth slows before olanzapine LAI, duvakitug, ecopipam and biosimilars start contributing, the market may again see Teva as relying on too few growth engines.

The commercial outlook rests on several milestones. AUSTEDO is growing strongly, but its new Medicare price will take effect on January 1, 2027, making 2026 a year in which investors will test not only sales but also margin durability ahead of that change. AJOVY received FDA approval in August 2025 for the preventive treatment of episodic migraine in children and adolescents aged 6 to 17, and in the U.S. it exited the quarter with 32.0% share of total prescriptions in the subcutaneous injectable anti-CGRP class, compared with 30.2% a year earlier. UZEDY has a new indication, but now has to show that broader use becomes recurring sales.

The pipeline is broader, but also layered with partner economics. Duvakitug has been in Phase 3 for Crohn’s disease and ulcerative colitis since October 2025, in collaboration with Sanofi. Olanzapine LAI is in regulatory review. DARI is in Phase 3 for asthma. TEV-408 has potential Royalty Pharma funding if it clears milestones. Biosimilars to Xgeva, Simponi, Simponi Aria, Eylea and Xolair are in review or submission pathways, with some dependent on partnerships with Alvotech or mAbxience. This is not an empty pipeline, but it is also not a pipeline where 100% of future economics necessarily belongs to Teva shareholders.

Investors also need to watch the external setting. The war involving Iran has already disrupted logistics corridors, maritime shipping routes and air cargo hubs, and in some cases has caused delays in production and distribution of pharmaceutical products and key inputs. The impact through March 31 was immaterial to results, but the risk is real. U.S. tariffs or reciprocal measures by other countries could also affect costs, supply chains and global operations. For a company with 48% of revenue denominated in currencies other than the dollar and a broad operating footprint, this is not just macro noise.

What has to happen over the next few quarters? First, operating cash flow needs to turn positive without greater dependence on receivables securitization. Second, marketing spend around the innovative products needs to look more like investment that creates operating leverage, not just a price paid to maintain growth. Third, Emalex needs to close on time without breaking the annual cash outlook. Fourth, legal liabilities need to keep declining, or at least avoid reopening through material follow-on claims.

Risks

The first risk is growth concentration. AUSTEDO, AJOVY and UZEDY explain most of the positive read in the quarter. That is good while they are growing, but risky if they become too central. AUSTEDO has broad U.S. patent protection and strong sales momentum, but the 2027 Medicare price is already set. AJOVY is growing in a competitive migraine market. UZEDY is early in its trajectory, with regulatory exclusivity expiring in April 2026, although it has a broader patent estate. The innovative products are not immune to competition, pricing and regulation.

The second risk is cash quality. In a quarter with positive net income and negative operating cash flow, the market should not be satisfied with a positive free-cash-flow line built from securitization and asset sales. The cash is real. But it is not the same as recurring cash from normal product sales, collection and better margins.

The third risk is debt. Debt is lower, the RCF is undrawn and the covenant appears under control. Still, $16.627 billion of debt, $2.600 billion of current maturities and annual legal payments of several hundred million dollars leave limited room for error if several engines weaken at once. Any repurchase program, if approved, will be judged against that backdrop.

The fourth risk is legal. Opioid settlements now look more like a payment schedule than an unmeasured cloud, but they still require hundreds of millions of dollars a year. In the European COPAXONE matter, the €462.6 million fine remains under appeal, backed by surety guarantees and possible post-decision interest. Generic competitors in Europe have also brought similar claims in Germany and the Netherlands, which are currently stayed. U.S. COPAXONE follow-on litigation and other competition matters remain active.

The fifth risk is pipeline execution. External funding reduces today’s expense burden but creates future obligations if the products succeed. If duvakitug, TEV-408, DARI or olanzapine LAI progress, Teva will have a stronger pipeline but will also share part of the value through milestones and royalties. If they are delayed, R&D reimbursements will not be enough to protect the thesis.

Conclusions

Teva opened 2026 with a quarter that strengthens its move from generics dependence toward a biopharma company with strong innovative-medicine engines. But the quarter also defines the next test: the improvement has to move from revenue and profitability into operating cash flow, without relying too heavily on receivables securitization, asset sales and collection timing. The market’s reaction over the next few quarters will depend not only on the sales trajectory of AUSTEDO, AJOVY and UZEDY, but also on how much cash remains after Emalex, litigation, debt and pipeline spending.

The company has already shown that its innovative medicines can offset a meaningful part of the erosion. It has not yet shown that those engines are enough for clean deleveraging.

What changed versus the prior cycle: the debt and legal questions did not disappear, but the commercial evidence improved. The quarter shows that innovative products keep growing despite lenalidomide erosion and the Japan divestiture. Cash quality did not improve at the same pace, so the key monitor remains operating cash flow, not only reported free cash flow.

The strongest counter-thesis is that the market may give too much credit to the biopharma pivot before cash confirms it. If innovative products keep growing but require high marketing spend, and if free cash flow remains dependent on securitization and asset sales, Teva will look less like a company entering a clean new phase and more like a company managing a long transition under debt.

What could change the near-term market read: one or two quarters of positive operating cash flow, a clean Emalex closing, a disciplined decision on repurchases, regulatory progress for olanzapine LAI and sales data showing that AUSTEDO, AJOVY and UZEDY keep growing even as U.S. generics erode.

Why it matters: Teva is no longer only a financial survival story, but it is not yet a clean growth story. Business quality improves when innovative medicines replace eroding generics. The investment-quality read improves only if that shift also reaches cash flow, debt reduction and capital allocation.